Form 4: Alkermes Director Brian McKeon Executes Equity Transactions

Director Brian P. McKeon acquired and disposed of Alkermes plc ordinary shares through stock option exercises and RSU vesting.

Summary

• Director Brian P. McKeon exercised options to acquire 6,142 ordinary shares on May 21, 2026.
• A total of 1,475 shares were withheld by the company at $36.95 per share to cover tax obligations related to the vesting of restricted stock units.
• The director was granted 11,538 non-qualified stock options and 5,409 restricted stock units on May 20, 2026.
• Following these transactions, the director holds 38,536 shares directly and 10,000 shares indirectly via a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions represent routine administrative equity management by a director rather than a strategic shift or market-moving event.

Positives

• Director maintains a significant equity stake in the company, aligning interests with shareholders.
• The acquisition of new equity awards indicates continued long-term commitment to the company.

Negatives

• The transaction involved the disposal of shares to satisfy tax withholding requirements, which is a standard but routine reduction in holdings.

Risks

• Future value of equity awards is subject to market volatility and the company's share price performance.

Future Outlook

The newly granted equity awards vest in full on the earlier of the one-year anniversary of the grant or the date of the next annual general meeting of shareholders occurring at least 50 weeks after the grant.

Management Comments

• The transactions were executed in accordance with standard equity compensation plans.

Industry Context

StockSavvy.ai notes that routine insider equity transactions, such as tax-related share withholding and annual grant cycles, are standard corporate governance practices in the biopharmaceutical sector and generally do not signal a change in company strategy.

Comparison to Industry Standards

• The use of RSU and stock option grants for directors is consistent with standard compensation practices for mid-to-large cap pharmaceutical companies.
• Tax withholding via share surrender is a common practice across the industry to manage executive tax liabilities.

Related Party Transactions

• The reporting person holds 10,000 shares through The Brian P. McKeon Revocable Trust, where the reporting person and his wife serve as trustees.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensation-related transactions.

Next Steps

• Vesting of the 11,538 stock options and 5,409 RSUs granted on May 20, 2026, expected within one year.

Key Dates

Keywords

Alkermes, ALKS, Director, Insider Trading, Equity Compensation, Form 4